Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of IN8bio's INB-100?
INB-100 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase I program in Acute Lymphocytic Leukemia (ALL,...